Abstract
Background Countermeasures against COVID-19 outbreaks such as lockdowns and voluntary restrictions against going out adversely affect human stress and economic activity. Particularly, this stress might lead to suicide.
Object We examined excess mortality attributable to suicide associated with COVID-19.
Method We applied the NIID model to suicide deaths by gender from October 2009 through August 2021 for the entirety of Japan. Effects of the great earthquake that struck eastern Japan on March 11, 2011 were incorporated into the estimation model. Results: Significant excess mortality by suicide was found during July 2020 and July 2021 for both genders. However, in August 2021, no excess mortality by suicide was observed among men; it was greater among women than among men. In all, 2950 excess cases of mortality were identified.
Discussion and Conclusion Excess mortality during the four months was more than double the number of COVID-19 deaths confirmed by PCR testing. Countermeasures against COVID-19 should be chosen carefully in light of such measures’ apparent exacerbation of suicide occurrence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All information used for this study was published on the web site of MHLW. Therefore, no ethical issue is presented.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ICMJE Statement Contributors TS was responsible for the organization and coordination of the study. JK was the chief investigator and responsible for the data setting. YO developed the estimation model. All authors contributed to the writing of the final manuscript.
We extend the data for one month. I revised the conclusion manuscript.
Data Availability
National Institute of Infectious Diseases, Excess mortality in Japan, on October 2020.
https://www.niid.go.jp/niid/ja/from-idsc/493-guidelines/10150-excess-mortality-21jan.html
